If ongoing research continues to deliver strong results, Cagrilintide could soon become part of the standard toolkit for treating obesity and metabolic disease, especially as a dual-therapy option alongside GLP-1s
For example, micronised creatine powder is typically flavourless, so it can be easily added to shakes
Semaglutide is often considered a game-changer for people with type 2 diabetes and those struggling with weight management, but its use should always be monitored by a healthcare provider
Its disadvantage relative to newer hair-focused peptides is the lack of dedicated clinical trials for hair as a primary endpoint
Despite all the changes, it seems likely that compounding pharmacies will continue to offer GLP-1 drugs, at least for the foreseeable future, says Brunner: Some patients will be able to maintain these therapies at a price point they can afford in a customized formulation. The Takeaway The FDA ordered compounding pharmacies to stop producing and selling copies of GLP-1 injectable drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, as official shortages have ended
